CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
Modafinil +1 moredrug
Likely dose
Modafinil 400 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03772314
NCT03772314Phase 2Completed

Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines

Emory University·interventional·Posted Dec 11, 2018·Updated May 23, 2024

In Brief

A Phase 2 clinical trial evaluating Modafinil and Amphetamine-Dextroamphetamine for Idiopathic Hypersomnia and Narcolepsy Without Cataplexy. Completed, enrolled 44 participants across 1 site.

Detailed Summary

For diseases that cause excessive daytime sleepiness (such as narcolepsy and idiopathic hypersomnia), there are several medications that can be used to treat sleepiness. However, it can be difficult to decide which medication to use for a particular individual for several reasons: 1) there are very few studies that directly compare two medications to see which works best; 2) there are very few studies that include people with a disorder of sleepiness called idiopathic hypersomnia. To address this gap in knowledge, the researchers propose a randomized clinical trial comparing modafinil and amphetamine salts in patients with narcolepsy type 2 or idiopathic hypersomnia. All participants will either receive modafinil or amphetamine salts - no participant will receive placebo. This study will evaluate which medication works better to improve sleepiness. The researchers will also see which medication is better for other symptoms including difficulty waking up and difficulty thinking, as well as seeing which medication causes fewer side effects. Finally, this study will see if any information about patients (such as age or sleep study features) predicts responding better to one medication or the other.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 11, 2018
Enrollment StartApr 15, 2019
Primary CompletionMay 4, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.6 years ago

Interventions

Modafinildrug

Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.

Amphetamine-Dextroamphetaminedrug

Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.